Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide

Ashley Munchel,1 Chimen Kesserwan,1 Heather J. Symons,1 Leo Luznik,2 Yvette L. Kasamon,2 Richard J. Jones,2 Ephraim J. Fuchs2

1Divisions of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA; 2Divisions of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Abstract

Allogeneic stem cell transplantation (SCT) from an HLA-haploidentical relative provides a potentially curative treatment option for hematologic malignancies patients who lack a suitably HLA-matched donor. The greatest challenge to performing HLA-haploidentical SCT has been high rates of graft failure and severe graft-versus-host disease (GVHD). Our group has been exploring high dose, post-transplantation cyclophosphamide (Cy) as prophylaxis of GVHD after nonmyeloablative, HLA-haploidentical bone marrow transplantation, or mini-haploBMT. Among 210 recipients of mini-haploBMT, 87% of patients have experienced sustained donor cell engraftment. The cumulative incidences of grades II-IV acute GVHD and chronic GVHD are 27% and 13%, respectively. Five-year cumulative incidence of non-relapse mortality is 18%, relapse is 55%, and actuarial overall survival and event-free survival are 35% and 27%, respectively. These outcomes suggest that mini-haploBMT with post-transplantation Cy is associated with acceptably low toxicities and can provide long-term survival, if not cure, for many patients with advanced hematologic malignancies.

Introduction

Post-transplantation Cy as a form of drug-induced immunologic tolerance

The idea of giving post-transplantation Cy came from studies that have shown that immunologic tolerance can be induced by the sequence of administering an antigen followed shortly by giving a drug to kill proliferating, antigen-reactive T or B cells. This phenomenon of drug-induced immunologic tolerance is not a new concept. It was initially reported in 1959 when it was shown that giving rabbits 6-mercaptopurine prevented their ability to produce antibodies against human serum albumin.1

Through a progression of studies it was found that Cy given one to three days after antigenic stimulation induces tolerance to tumor, skin grafts or other solid organ transplants in murine models.2,4 The proposed mechanism has been clonal destruction of alloreactive T cells.5 In other words, antigenic stimulation from the graft causes rapid proliferation of T-cell clones specific to the foreign antigen. When Cy is given at the height of proliferation, 1-3 days after stimulation, it inhibits DNA replication and results in selective destruction of alloreactive T-cell clones. In vitro studies have shown this occurs in mature T cells only.6 Importantly, Cy may not kill those quiescent T cells that were not activated by administration of the antigen. These cells include pathogen-specific memory T cells, and this explains why immunity to infection is spared among patients treated with high dose Cy outside the context of allogeneic SCT. Thus, the tolerance induced by post-transplantation Cy is specific to the administered antigen. When the antigen administered is allogeneic cells, post-transplantation Cy induces selective alloredeption.

Phase II trial of nonmyeloablative, HLA-haploidentical BMT with high-dose post-transplantation cyclophosphamide

Based upon encouraging results from a phase I trial,7,8 we recently completed a phase II trial of nonmyeloablative, HLA-haploidentical BMT with high-dose, post-transplantation Cy for patients with advanced hematologic malignancies. As of September 14th, 2010, 210 consecutive patients received nonmyeloablative, HLA-haploidentical transplantation with high-dose, post-transplantation cyclophosphamide and had at least one year of follow-up. Details concerning criteria for eligibility, HLA typing, outcomes measures, and statistical analysis have been published previously.8,9

The treatment regimen given to all patients is shown in Figure 1. All patients were intended to be treated as outpatients. Conditioning comprised cyclophosphamide 14.5 mg/kg/day on days -6 and -5, fludarabine 30 mg/m²/day for five consecutive days starting on day -6, and 2 Gy total body irradiation given in a single fraction on day -1. Bone marrow was harvested from donors and infused into recipients on day 0. There was no manipulation to deplete graft T-cells. GVHD prophylaxis consisted of cyclophosphamide 50 mg/kg IV, together with Mesna, each on days 3 and 4, mycophenolate mofetil 15 mg/kg po tid (maximum 3 g/day) from day 5-35, and tacrolimus from day 5-180. Tacrolimus levels were monitored at least weekly with a desired concentration from 5-15 ng/ml. Prophylactic antimicrobial therapy was started on day -6 and included norfloxacin, fluconazole, appropriate prophylaxis of Pneumocystis carinii pneumonia, and valacyclovir.

Characteristics of the patients, donors, and grafts are shown in Table 1. All patients had poor risk hematologic malignancies that were judged to be incurable by chemotherapy alone. Fifty-eight patients had experienced relapse of their original malignancy after a prior autologous transplantation procedure, including 22 of the 30 patients with Hodgkin lymphoma and 23 of the 66 patients with non-Hodgkin lymphoma. Donors were selected primarily on the basis of health status, lack of anti-donor HLA antibodies in the recipient, and ABO and CMV compatibility, and without regard for the degree of HLA mismatch between donor and recipient.

Engraftment and donor chimerism

Of the 210 patients transplanted, 204 were evaluable for donor cell engraftment. Twenty-seven patients (13%) failed to engraft. Nearly all patients with primary or secondary graft
failure experienced recovery of autologous hematopoiesis. As reported previously, the median time to a neutrophil count of ≥500/μL was 15 days, and the median time to an unsupported platelet count of ≥20,000/μL was 24 days.

GVHD

Figure 2 shows that the cumulative incidence of grade 2-4 aGVHD was 27%, grade 3-4 aGVHD was 5% and chronic GVHD was 13%. This coincides with the data previously reported in the 67 patients, which had shown a cumulative incidence of grade 2-4 aGVHD of 34%, grade 3-4 aGVHD of 6%.

Relapse and nonrelapse mortality

The cumulative incidences of relapse and nonrelapse mortality were 55% and 18%, respectively (Figure 3). One hundred thirteen

![Figure 1. Treatment schema for nonmyeloablative conditioning regimen in HLA-haploidentical transplantation with post-transplantation cyclophosphamide. MMF=mycophenolate mofetil; TBI=total body irradiation; Cy=cyclophosphamide; G-CSF=granulocyte colony stimulating factor.](image)

![Figure 2. Cumulative incidence of acute (A) and chronic (B) GVHD after nonmyeloablative haploidentical stem cell transplantation with post-transplantation cyclophosphamide. n=210](image)

<table>
<thead>
<tr>
<th>Table 1. Patient, donor, and graft characteristics.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient age (median, range)</td>
</tr>
<tr>
<td>Sex (male/female)</td>
</tr>
<tr>
<td>Diagnoses:</td>
</tr>
<tr>
<td>Acute myeloid leukemia</td>
</tr>
<tr>
<td>Acute lymphocytic leukemia</td>
</tr>
<tr>
<td>Chronic myeloid leukemia</td>
</tr>
<tr>
<td>Chronic lymphocytic leukemia</td>
</tr>
<tr>
<td>Myelodysplastic syndrome</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
</tr>
<tr>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>Myeloproliferative disorder</td>
</tr>
<tr>
<td>Donor age (median, range)</td>
</tr>
<tr>
<td>Parents</td>
</tr>
<tr>
<td>Siblings or half-siblings</td>
</tr>
<tr>
<td>Children</td>
</tr>
<tr>
<td>Graft nucleated cell dose (x 10⁸/kg)</td>
</tr>
<tr>
<td>T cell dose (x 10⁷/kg)</td>
</tr>
<tr>
<td>CD34+ cell dose (x 10⁶/kg)</td>
</tr>
<tr>
<td>Median donor/recipient HLA antigen mismatch</td>
</tr>
</tbody>
</table>

*Patients and donors were typed at high resolution for HLA-A, -B, -Cw, -DRB1, and -DQB1.
patients have died. The causes of death were relapse (n=79), infection (n=15), pulmonary complications (n=7), GVHD (n=5), other (n=4), or unknown (n=3).

### Overall and event-free survival

Three-year overall survival and event-free survival are 41% and 32% respectively (Figure 4). Three year overall survival was 50% for patients transplanted for acute lymphocytic leukemia, 45% for patients transplanted for myelodysplastic syndrome or myeloproliferative disorder, and 35% for patients transplanted for acute myeloid leukemia (Figure 4B). Three year survival was 62% for 30 patients with Hodgkin lymphoma (22 of whom had undergone prior autologous SCT), 41% for patients with non-Hodgkin lymphoma, and only 22% for patients with chronic lymphocytic leukemia (Figure 4C).

### Effect of HLA-disparity on outcome of HLA-haploidentical SCT with post-transplantation cyclophosphamide

Previous studies of T cell-replete, HLA-haploidentical BMT after myeloablative conditioning have shown that increasing HLA mismatch between donor and recipient was associated with worse survival due to an increased incidence of GVHD and NRM, which outweighed any potential reduction in the incidence of relapse. Since our regimen incorporated nonmyeloablative conditioning and novel GVHD prophylaxis, we examined the impact of increasing HLA disparity on outcome.

![Figure 4. Actuarial curves of (A) overall survival (OS) and event-free survival (EFS) in all patients undergoing nonmyeloablative haploidentical stem cell transplantation with post-transplantation cyclophosphamide; (B) overall survival in patients with acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML) or myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD); (C) overall survival in patients with Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and chronic lymphocytic lymphoma (CLL).](image-url)
Interestingly, Figure 5 shows a trend to improved event-free survival with increasing HLA antigen disparity between donor and recipient (HR = 0.80; 95% confidence interval [CI] = 0.66-0.96; P = .02), with the hazard ratio of 0.8 indicating a 20% reduction in the risk of an event (death or relapse) for each increment of HLA mismatch. An HLA-DRB1 antigen mismatch in the graft-versus-host direction, and two or more HLA Class I (HLA-A, -B, and -Cw) mismatches in either direction were found to be associated with decreased incidences of relapse without an increased incidence of non-relapse mortality (data not shown). While an analysis of the effects of NK cell alloreactivity on outcome is ongoing, we have previously found that donor-recipient mismatches at genes for inhibitory Killer Immunoglobulin-like Receptors, or iKIRs, or KIR haplotypes, were associated with improved outcome of nonmyeloablative, HLA-haploidentical BMT with post-transplantation cyclophosphamide.

**Discussion**

The major advantage of HLA-haploidentical stem cell transplantation is rapid and near universal availability of one or more donors, since all biological parents and children, and 50% of siblings or half-siblings of a patient are HLA-haploidentical. Indeed, in our clinical trial the patients have had an average of four potential HLA-haploidentical donors for transplantation. The major disadvantages of this approach have been the consequences of intense bi-directional alloreactivity, i.e. high incidences of graft failure, severe GVHD, non-relapse mortality, and severe opportunistic infections resulting from poor immune reconstitution. High-dose, post-transplantation Cy was developed in mouse models of solid organ and hematopoietic stem cell transplantation as a method of achieving selective depletion of alloreactive T cells in vivo.1,2,4,14-17 The studies described here show that high dose, post-transplantation Cy enables HLA-haploidentical stem cell transplantation after nonmyeloablative conditioning with acceptably low incidences of fatal graft rejection, severe GVHD, and non-relapse mortality. The low death rate from opportunistic infection is testimony to effective clinical immune reconstitution after transplantation. Interestingly, post-transplantation Cy appears to nullify the detrimental impact of HLA mismatching on the outcome of allogeneic SCT for hematologic malignancies.9 The practical consequence of this finding is that stem cell donors may be selected without regard to the degree of donor-recipient HLA mismatching, and on the basis of biologic or genetic characteristics other than HLA genes. For example, we are currently conducting a clinical trial of nonmyeloablative allogeneic SCT and post-transplantation rituximab therapy of lymphoma, in which donors are selected according to Fc(γ)RIIIa (CD16) genetic polymorphisms that predict clinical responsiveness to rituximab therapy.18,19 HLA-haploidentical SCT expands access to transplantation for patients with sickle cell disease, who have an 18% chance of having a disease-free, HLA-matched sibling.20 We are currently testing whether post-transplantation Cy permits HLA mismatching in unrelated donor transplantation. If so, it may be possible to select unrelated donors who are partially HLA mismatched but who harbor a mutation in the gene for the CCR5 receptor for the human immunodeficiency virus. Such individuals are genetically resistant to HIV infection, and as donors could provide a cure for AIDS through allogeneic stem cell transplantation.21,22 These examples provide a taste of the therapeutic possibilities enabled by a successful crossing of the HLA barrier. We are currently characterizing phenotypic and functional immune reconstitution after allogeneic SCT with post-transplantation Cy, and the mechanisms of Cy-induced tolerance in the human. With improvements in our understanding of Cy-induced tolerance,23 and with continued efforts to improve the safety and efficacy of HLA-haploidentical SCT, we hope to offer this approach to cure increasing numbers of children and adults with hematologic malignancies,24 and extend this treatment to patients with life-threatening, non-malignant hematologic disorders.

**References**


